1. Cystic fibrosis and neonatal screening.
- Author
-
Rodrigues R, Gabetta CS, Pedro KP, Valdetaro F, Fernandes MI, Magalhães PK, Januário JN, and Maciel LM
- Subjects
- Antigens, Neoplasm blood, Biomarkers, Tumor blood, Black People, Cystic Fibrosis genetics, Cystic Fibrosis Transmembrane Conductance Regulator blood, Cystic Fibrosis Transmembrane Conductance Regulator genetics, DNA analysis, Humans, Immunohistochemistry, Incidence, Infant, Newborn, Lectins, C-Type blood, Pancreatitis-Associated Proteins, Prenatal Diagnosis, Trypsin blood, United States epidemiology, White People, Black or African American, Cystic Fibrosis diagnosis, Neonatal Screening
- Abstract
The clinical and diagnostic aspects of cystic fibrosis have been extensively reviewed, with an emphasis on neonatal screening. This systematic literature review involved a search for relevant contributions in the PubMed and SciELO databases. The first references to cystic fibrosis date to the Middle Ages. Cystic fibrosis is the most frequent autosomal recessive hereditary disease among Caucasians (1:2,000 to 3,500). More than 1,000 mutations lead to the disease, the most common being "F508, with 70% prevalence among Canadian, Northern European, and American Caucasians and 23 to 55% prevalence among Brazilians. The basic defect is in chloride ion secretion. Cystic fibrosis screening has long been controversial, and after almost three decades, there are few nationwide programs (most are regional or local). However, the U.S. Centers for Disease Control and Prevention (CDC) has concluded that screening for cystic fibrosis is justified. The lack of a specific screening test and the ethnic heterogeneity of the Brazilian population pose challenges for neonatal screening.
- Published
- 2008
- Full Text
- View/download PDF